Search results

Making a submission

Search Results

Respecting your privacy

Sitemap

Freedom of information

progesterone (Lubion)

Indicated in adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.

fluticasone/formoterol (flutiform k-haler)

Indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. • flutiform k-haler) is indicated in adults and adolescents aged 12 years and above.

obinutuzumab (Gazyvaro)

In combination with chemotherapy, followed by maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma (FL).

tocilizumab (RoActemra)

For the treatment of Giant Cell Arteritis (GCA) in adult patients.

dupilumab (Dupixent)

For treatment of moderate-to-severe atopic dermatitis.

sapropterin (Kuvan)

Treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.

lacosamide (Vimpat)

As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy

dexamethasone 40mg tablets (Neofordex)

In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products

clostridium botulinum type A toxin-haemagglutinin complex 300 and 500 units (Dysport)

Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.

tofacitinib (Xeljanz)

In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.